What question did this study set out to answer?

The aim is to understand the mechanisms of resistance to EGFR inhibitors in non-small cell lung cancer (NSCLC) and explore new therapeutic strategies.

June 11, 2026International Journal of Molecular SciencesOpen Access

Resistance to EGFR Inhibitors in NSCLC: Mechanistic Insights and Emerging Therapies

View Full Paper

Ask AI

Bookmark

The aim is to understand the mechanisms of resistance to EGFR inhibitors in non-small cell lung cancer (NSCLC) and explore new therapeutic strategies.
Review of mechanisms related to EGFR resistance, including T790M and C797S mutations.
Discussion of emerging therapies, including next-generation TKIs and immunotherapy approaches.
Analysis of current strategies aimed at overcoming resistance in NSCLC.
Approximately 50% of resistance cases post-TKIs are due to T790M mutations.
Osimertinib shows a median progression-free survival of 18.9 months.
Diverse emerging therapies include combination targeted approaches and immunotherapeutic methods.

Discussion

No takes yet. Share an insight, caveat, or question.

Implication

Review discusses resistance mechanisms and therapies to improve outcomes in EGFR-mutant NSCLC.

Cite This Study

Khoury et al. (2026) studied this question.

synapsesocial.com/papers/6a2a526080c8f91e7f39e63b https://doi.org/10.3390/ijms27125197

View Full Paper

Ask AI

Bookmark

Resistance to EGFR Inhibitors in NSCLC: Mechanistic Insights and Emerging Therapies

Key Points

Discussion

Implication

Cite This Study

Resistance to EGFR Inhibitors in NSCLC: Mechanistic Insights and Emerging Therapies

Key Points

Discussion

Implication

Cite This Study

Also Consider

Also Consider